Lutathera demonstrated antitumor exercise in metastatic bronchopulmonary neuroendocrine tumors: © inventory.adobe.com.
Lutathera confirmed antitumor exercise in sufferers with metastatic bronchopulmonary neuroendocrine tumors, primarily based on real-world knowledge offered on the IASLC 2025 World Convention on Lung Most cancers.
Amongst sufferers handled with Lutathera (23 sufferers), partial responses, steady illness and progressive illness occurred in 17%, 30% and 23% of sufferers, respectively.
“In medical apply, the choice of when to make the most of peptide receptor radionuclide remedy varies broadly, discovered right here mostly as a third-line systemic agent,” Dr. Giuseppe Maiocco, a resident within the Division of Inner Drugs on the Mayo Clinic and coauthors wrote in a poster presentation.
What Are the Background and Design of this Actual-World Research?
Lutathera is a peptide receptor radionuclide remedy and has emerged as a promising therapy in neuroendocrine tumors with selective focusing on of somatostatin receptor–expressing cells.
In April 2024, the FDA permitted Lutathera for the therapy of sufferers 12 years of age or older with somatostatin receptor–constructive gastroenteropancreatic neuroendocrine tumors. This regulatory resolution represented the primary FDA approval of a radioactive drug or radiopharmaceutical for this affected person inhabitants.
Of be aware, BP-NETs comprise roughly 20% to 30% of neuroendocrine tumors and the administration of metastatic BP-NETs requires substantial tailoring. Accordingly, the target of this real-world research was to guage the real-world use of Lutathera in sufferers with BP-NETs.
Within the retrospective evaluation, sufferers with metastatic BP-NETs have been handled with peptide receptor radionuclide remedy at Mayo Clinic websites in Arizona, Florida and Minnesota between 2014 and 2025. Notably, tumor grade was outlined by Ki-67 rating and histology was outlined per World Well being Group 2017 standards.
Main outcomes included response charges, progression-free survival and total survival. Response charges have been assessed by 3-month post-treatment interval restaging imaging and clinician doc evaluation. Development-free survival was outlined as remedy initiation to any illness development, final follow-up or dying; total survival was outlined as remedy initiation to final follow-up or dying.
What Had been the Baseline Affected person Traits?
Within the affected person inhabitants, the median age was 66 years, 39% have been feminine and 48% had a historical past of tobacco use. Metastatic websites included liver (78%), bone (61%), pancreas (9%) and contralateral lung (4%). Moreover, sufferers had grade 1 (26%), grade 2 (39%) or grade 3 (26%) illness per World Well being Group 2017 standards. Carcinoid histology was both typical (43%) and atypical (57%). Moreover, the vast majority of sufferers have been nonfunctional (70%), had a Krenning scale rating of 4 (57%) and an ECOG efficiency standing of 0 (57%). The median variety of remedy remedies was 4. Relating to therapy historical past, greater than half of sufferers acquired 2 systemic remedies earlier than remedy (52%). Previous remedies included somatostatin analog (100%), chemotherapy (65%) with 43% of sufferers handled with single-line chemotherapy, Afinitor (43%) and a tyrosine kinase inhibitor (9%). Notably, 43% of sufferers didn’t obtain systemic remedies following remedy.
What Different Efficacy and Security Information Had been Reported?
In all sufferers, the median progression-free survival was 10.8 months. Furthermore, in sufferers with typical and atypical carcinoid histology, the median progression-free survival was 11.1 months and eight.4 months. These with a Krenning rating of 4 and a Krenning rating of three or much less had a median progression-free survival of 14.7 months and seven.3 months.
The median total survival in all sufferers was 35.6 months. Sufferers with typical and atypical carcinoid histologies had a median total survival of 35.5 months and 19.8 months. Sufferers with a Krenning rating of 4 or a Krenning rating of three or much less had a median total survival of 24.4 months and 16.5 months.
Relating to negative effects, the commonest treatment-related negative effects included fatigue (35%), nausea (26%), belly ache (22%) and decreased urge for food (13%).
“Lutathera was properly tolerated, with no grade 3 or greater negative effects,” Maiocco and coauthors concluded within the poster presentation.
References
- Maiocco G, Hazim A, Halfdanarson T, et al. Actual-world outcomes of sufferers with bronchopulmonary neuroendocrine tumors handled with Lutetium Lu-177 dotatate. Offered at: Worldwide Affiliation for the Research of Lung Most cancers 2025 World Convention on Lung Most cancers; September 6-9, 2025; Barcelona, Spain. Summary P3.13.32.
- FDA approves lutetium Lu 177 dotatate for pediatric sufferers 12 years or older with GEP-NETS. FDA. April 23, 2024. Accessed September 9, 2025. https://www.fda.gov/medication/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets
